% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{MarcosMorgado:282304,
author = {Marcos Morgado, Barbara and Klafki, Hans-Wolfgang and
Bauer, Chris and Waniek, Katharina and Esselmann, Hermann
and Wirths, Oliver and Hansen, Niels and Lachmann, Ingolf
and Osterloh, Dirk and Schuchhardt, Johannes and Wiltfang,
Jens},
title = {{A}ssessment of immunoprecipitation with subsequent
immunoassays for the blood-based diagnosis of {A}lzheimer's
disease.},
journal = {Archiv für Psychiatrie und Nervenkrankheiten},
volume = {Advance online publication},
issn = {1433-8491},
address = {Heidelberg},
publisher = {Springer},
reportid = {DZNE-2025-01274},
pages = {-},
year = {2024},
note = {ISSN 1433-8491 not unique: **2 hits**.},
abstract = {The Aβ42/40 ratio and the concentration of phosphorylated
Tau181 in blood plasma represent attractive biomarkers for
Alzheimer's disease. As a means for reducing potential
matrix effects, which may interfere with plasma
immunoassays, we have previously developed a pre-analytical
sample workup by semi-automated immunoprecipitation. Here we
test the compatibility of pre-analytical
immunoprecipitations with automated Aβ1-40, Aβ1-42 and
phosphorylated Tau181 immunoassays on the Lumipulse platform
and compare the diagnostic performance of the respective
immunoprecipitation immunoassay approaches with direct
plasma measurements. 71 participants were dichotomized
according to their Aβ42/40 ratios in cerebrospinal fluid
into the diagnostic groups amyloid-positive (n = 32) and
amyloid-negative (n = 39). The plasma Aβ1-42/1-40 ratio and
phosphorylated Tau181 levels were determined on the
Lumipulse G600II platform (Fujirebio) by direct measurements
in EDTA-plasma or after Aβ- or Tau-immunoprecipitation,
respectively. Pre-analytical immunoprecipitation of Aβ
turned out to be compatible with the Lumipulse Aβ assays
and resulted in a numerical, yet statistically not
significant increase in the area under the ROC curve for
plasma Aβ1-42/1-40. Additionally, we observed a significant
increase in the standardised effect size (Cohen's D).
Pre-analytical immunoprecipitation of Tau resulted in
increased differences between the diagnostic groups in terms
of median and mean phosphorylated Tau 181 levels.
Furthermore, we observed a greater Cohen's d (p < 0.001) and
a larger area under the ROC curve (p = 0.038) after Tau-IP.
Our preliminary findings in a small, preselected sample
indicate that pre-analytical immunoprecipitation may have
the potential to improve the diagnostic performance of
plasma biomarker immunoassays for Aβ1-42/1-40 and
phosphorylated Tau181 to predict brain amyloid deposition.},
keywords = {Alzheimer’s disease (Other) / Amyloid beta (Other) /
Biomarker (Other) / Blood plasma (Other) / Tau (Other)},
cin = {AG Wiltfang},
ddc = {610},
cid = {I:(DE-2719)1410006},
pnm = {353 - Clinical and Health Care Research (POF4-353)},
pid = {G:(DE-HGF)POF4-353},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:38316685},
doi = {10.1007/s00406-023-01751-2},
url = {https://pub.dzne.de/record/282304},
}